Entrada Therapeutics

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald previously served as Entrada's Vice President of Corporate Communications and Investor Relations. She remains a member of the Entrada executive team and will report to Dipal Doshi, Entrada's President and Chief Executive Officer.

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the Company will participate in-person at the William Blair Biotech Focus Conference, to be held in New York from July 12 – 13, 2022.

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Bionomics Ltd

Esports Entertainment Group

Kiromic Biopharma

Lesaka Technologies Inc

PureCycle Technologies

PMV Pharmaceuticals

Vigil Neuroscience

We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday appeared first on InvestorPlace.

Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the Company will participate in-person at the Goldman Sachs Global Healthcare Conference. A fireside chat with Dipal Doshi, President and Chief Executive Officer will be held at Terranea in Rancho Palos Verdes, CA on Tuesday, June 14, 2022 at 2:40 p.m. Pacific Time/5:40 p.m. Eastern Time.

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1

Entrada Therapeutics Reports First Quarter 2022 Financial Results

New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

Aterian

Newegg Commerce

Beam Global

Clever Leaves Holdings Inc

Short squeeze stocks are trending this morning following the release of Fintel's weekly short-squeeze ranking. Which companies are on top?

Short Squeeze Stocks: ATER, NEGG and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference. The panel will be held on Monday, March 7, 2022 at 9:10 a.m. Eastern Time.

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.

Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes as part of the planned fourth quarter IPO additions, effective after the U.S. market opens on December 20, 2021.

Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes

Successful completion of upsized $208.7 million Initial Public Offering

Entrada Therapeutics Reports Third Quarter 2021 Financial Results

BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world's foremost intracellular therapeutics company, today announced the closing of its initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share. All shares were offered by Entrada. The gross proceeds to Entrada from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $181.5 million. The shares began trading on The Nasdaq Global Market under the ticker symbol “TRDA” on October 29, 2021. In addition, the underwriters have a 30-day option to purchase up to an additional 1,361,250 shares of common stock at the initial public offering price less underwriting discounts and commissions.

Entrada Therapeutics Announces Closing of Initial Public Offering

Arteris

AirSculpt Technologies

Augmedix

Aura Biosciences

Solo Brands

Fluence Energy

GlobalFoundries

HireRight GIS Group Holdings LLC

LF Capital Acquisition Corp II

Marpai

Rent the Runway

Sonendo

Udemy

Sweetgreen

The IPO market remained active this past week as 13 IPOs raised $6.3 billion. SPAC activity kept steady with 13 blank check IPOs raising $2.1 billion.

U.S. IPO Weekly Recap: Semiconductors And Energy Storage Lead A Spooky 14 IPO Week

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world's foremost intracellular therapeutics company, today announced the pricing of its upsized initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share. All shares are being offered by Entrada. The gross proceeds to Entrada from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $181.5 million. The shares are expected to begin trading on The Nasdaq Global Market under the ticker symbol “TRDA” on October 29, 2021. The offering is expected to close on November 2, 2021, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,361,250 shares of common stock at the initial public offering price less underwriting discounts and commissions.

Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering

Entrada Therapeutics has filed to raise $150 million in an IPO. The firm is developing treatments for various neurodegenerative diseases.

Entrada Therapeutics Seeks $150 Million U.S. IPO

News for Entrada Therapeutics Stock (TRDA)